- About Us
- Nano-Social Network
- Nano Consulting
- My Account
· CEO Dr Jackie Fairley presenting at the Citi Annual Australian and New Zealand Conference in London, 6th March 2012.
· Premier opportunity to further develop relationships with offshore investors.
· Starpharma selected as one of only four leading healthcare companies to present alongside 36 ASX listed companies.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is one of four leading Australian healthcare companies invited to present at the 9th Citi Annual Australian and New Zealand Conference in London.
Commencing today, the conference is expected to be attended by more than 200 people including the leading institutional investors from London and Europe. Thirty six top ASX listed companies have been invited to present, most of which are in the ASX 100 index. The other Australian healthcare companies presenting are Cochlear Ltd, Sonic Healthcare Ltd and QRxPharma.
Starpharma Chief Executive Officer Dr Jackie Fairley said the Conference is an excellent opportunity to detail Starpharma's continuing progress and its strong links to the UK and Europe, including the recent investment by major UK based global fund M&G, which now holds 7% of Starpharma.
"We are delighted to present at the Conference alongside our peers and feel it's timely in consideration of our recent achievements and the expansion of our global investor footprint," said Dr Fairley.
In addition, Starpharma will be presenting at the ASX Emerging Growth Conference also in London on Thursday 8th March. In its fourth year, this London conference features a selection of emerging market leaders in the small to mid cap segment of the Australian public market.
As both conferences Dr Fairley will detail Starpharma's maturing development portfolio across sexual and women's health, drug delivery and agrochemical platforms. She will also discuss important upcoming commercial milestones.
Highlights of the presentation include:
VivaGel® Bacterial Vaginosis program: The European Medicines Agency (EMA) recently agreed to a Phase 3 clinical trial program for VivaGel® as a treatment for bacterial vaginosis (BV), in addition to the agreement reached with the US Food and Drug Administration (FDA) which includes Special Protocol Assessment (SPA) by FDA. A Phase 2 study of prevention of recurrence of BV is also underway.
Drug delivery program: Starpharma's dendrimer-docetaxel formulation was found recently to be significantly more effective than leading cancer drug docetaxel (Taxotere®) in breast cancer model.
Agrochemical program: The improved performance of market leading agrochemical candidates including glyphosate (active ingredient in Roundup®) when formulated with Starpharma's dendrimers.
Financials: Starpharma completed a A$35 million capital raising late last year firming up its strong cash position to $49 million at 31 December 2011. Net cash outflow from operations was $3.9 million.
For more information, please click here
LEVEL 13 499 ST KILDA ROAD
MELBOURNE AUSTRALIA 3004
TEL +61 3 8866 1210
MOB +61 (0) 423 139 163
Dr Jackie Fairley
Chief Executive Officer
Copyright © Starpharma Holdings LimitedIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Explaining how 2-D materials break at the atomic level January 20th, 2017
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Nanometrics to Present at the 19th Annual Needham Growth Conference December 22nd, 2016